Literature DB >> 11749694

Aberrations of the p14(ARF) and p16(INK4a) genes in renal cell carcinomas.

Y Kawada1, M Nakamura, E Ishida, K Shimada, E Oosterwijk, H Uemura, Y Hirao, K S Chul, N Konishi.   

Abstract

The INK4a / ARF locus on chromosome 9p21, which encodes two distinct genes, p14(ARF) and p16(INK4a), is frequently altered in human neoplasms. To investigate the potential roles of p14(ARF) and p16(INK4a) genes in human renal cell carcinomas (RCCs), we analyzed 6 human RCC cell lines and 91 primary RCCs for homozygous deletion, promoter hypermethylation and expression of the p14(ARF) and p16(INK4a) gene products using differential PCR, methylation-specific PCR, and immunohistochemistry, respectively. Five cell lines showed homozygous co-deletion of both genes and one demonstrated promoter hypermethylation of the p16(INK4a) gene only. Eight of 91 RCCs showed aberrations of p14(ARF) or p16(INK4a) status and six of these featured gross extension into the renal vein. The results suggest that p14(ARF) and p16(INK4a) aberrations may play roles in the relatively late stage of renal tumorigenesis associated with tumor progression.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11749694      PMCID： PMC5926680          DOI： 10.1111/j.1349-7006.2001.tb02152.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  45 in total

1.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

2.  Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status.

Authors:  M Esteller; S Tortola; M Toyota; G Capella; M A Peinado; S B Baylin; J G Herman
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

3.  Role of the INK4a locus in tumor suppression and cell mortality.

Authors:  M Serrano; H Lee; L Chin; C Cordon-Cardo; D Beach; R A DePinho
Journal:  Cell       Date:  1996-04-05       Impact factor: 41.582

4.  Allelotype of renal cell carcinoma.

Authors:  R Morita; J Ishikawa; M Tsutsumi; K Hikiji; Y Tsukada; S Kamidono; S Maeda; Y Nakamura
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

5.  Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.

Authors:  M Nakamura; T Sakaki; H Hashimoto; H Nakase; E Ishida; K Shimada; N Konishi
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

6.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.

Authors:  D E Quelle; F Zindy; R A Ashmun; C J Sherr
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

7.  Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas.

Authors:  P Cairns; K Tokino; Y Eby; D Sidransky
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

8.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Cooperative tumorigenic effects of germline mutations in Rb and p53.

Authors:  B O Williams; L Remington; D M Albert; S Mukai; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330

10.  p53 mutations occur in clinical, but not latent, human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; I Hayashi; H Matsuda; T Tsuzuki; T Ming; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Jpn J Cancer Res       Date:  1995-01
View more
  7 in total

1.  Infrequent alteration of the DPC4 tumor suppressor gene in renal cell carcinoma.

Authors:  Marijana Popović Hadzija; Reno Hrasćan; Maja Herak Bosnar; Zarko Zeljko; Mirko Hadzija; Josip Cadez; Kresimir Pavelić; Sanja Kapitanović
Journal:  Urol Res       Date:  2004-04-24

Review 2.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

Review 3.  Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies.

Authors:  Ismail El-Mokadem; John Fitzpatrick; Bhavan Rai; J Cunningham; Norman Pratt; Stewart Fleming; Ghulam Nabi
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

4.  Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.

Authors:  I El-Mokadem; J Fitzpatrick; J Bondad; P Rauchhaus; J Cunningham; N Pratt; S Fleming; G Nabi
Journal:  Br J Cancer       Date:  2014-08-19       Impact factor: 7.640

5.  Novel genomic alteration in superficial esophageal squamous cell neoplasms in non-smoker non-drinker females.

Authors:  Yusuke Onozato; Yu Sasaki; Yasuhiko Abe; Hidenori Sato; Makoto Yagi; Naoko Mizumoto; Takashi Kon; Takayuki Sakai; Minami Ito; Matsuki Umehara; Ayumi Koseki; Yoshiyuki Ueno
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

6.  Epstein-Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma.

Authors:  Ali Farhadi; Sepide Namdari; Pei Pei Chong; Bita Geramizadeh; Abbas Behzad-Behbahani; Zamberi Sekawi; Sedigheh Sharifzadeh
Journal:  BMC Urol       Date:  2022-02-07       Impact factor: 2.264

7.  Clinical significance of p16INK4A and p14ARF promoter methylation in renal cell carcinoma: a meta-analysis.

Authors:  Yu Ren; Li Xiao; Guobin Weng; Bingyi Shi
Journal:  Oncotarget       Date:  2017-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.